Core Insights - Firefly Neuroscience, Inc. has announced a partnership with the Department of War to support the assessment and treatment of PTSD and TBI among U.S. service members and veterans, marking a significant expansion into the U.S. government and defense health sectors [1][5] Industry Context - PTSD and TBI are major health challenges for the U.S. military, with the economic burden of PTSD estimated at $232.2 billion, of which $42.7 billion is attributed to the military population [3] - The incidence of TBI is notably higher in military personnel compared to civilians, with over 444,300 service members diagnosed with at least one TBI from 2000 to 2021 [3][4] Company Technology - Firefly's FDA-cleared, AI-powered EEG/ERP platform is designed to provide military healthcare providers with objective neurological data for precise diagnosis and individualized treatment planning [5][6] - The technology is non-invasive and scalable, suitable for both clinical and operational environments, and aims to fill the gap in objective diagnostic tools for military mental health [4][5] Strategic Positioning - The partnership with the Department of War is expected to enhance Firefly's commercial strategy by expanding its footprint in the U.S. government and defense health sectors [5][6] - The company aims to leverage its growing repository of brain scan data and NVIDIA GPU acceleration to develop a proprietary foundation model of the human brain [6]